Checkpoint Therapeutics, Inc.
CKPTDelisted May 30, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001651407
Checkpoint Therapeutics, Inc. was delisted on May 30, 2025; its insiders filed their last Form 4 on Jun 3, 2025; 84 institutions reported holding it in 13F filings for Q1 2025, worth $137.7M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Checkpoint Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Checkpoint Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Fortress Biotech, Inc. | 10% Owner | 0 | Jun 3, 2025 | 0 |
| Rosenwald Lindsay A MD | Director | 0 | May 30, 2025 | 0 |
| Weiss Michael S | Director | 0Indirect | May 30, 2025 | 0 |
| Herskowitz Neil | Director | 0 | May 30, 2025 | 0 |
| Bechon Christian | Director | 0 | May 30, 2025 | 0 |
| Salzman Barry M | Director | 0 | May 30, 2025 | 0 |
| Oliviero James F III | CEO, President and Director | 0 | May 30, 2025 | 0 |
| Gray William Garrett | Chief Financial Officer | 0 | May 30, 2025 | 0 |
| Amit Sharma | Director | 0 | May 30, 2025 | 0 |
| Boilen Scott | Director | 37,345 | Jun 15, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2025 (view filing) | May 29 | 5 daysLate | Fortress Biotech, Inc.10% Owner | SSaleCOMMON STOCK, PAR VALUE $0.0001 | −100.0K | $1.29 | −$129.0K | −1.6%6.12M after | |
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Oliviero James F IIICEO, President and Director | SSale | −15.1K | $4.04 | −$61.0K | −0.4%3.76M after | |
| Apr 3, 2025 (view filing) | Apr 1 | 2 days | Gray William GarrettChief Financial Officer | SSale | −12.3K | $4.05 | −$49.9K | −0.8%1.45M after | |
| Feb 11, 2025 (view filing) | Feb 7-10 | 4 days | Oliviero James F IIICEO, President and Director | SSale | −19.6K | $3.27 | −$64.0K | −0.5%3.78M after | 2 lots |
| Feb 7, 2025 (view filing) | Feb 6 | 1 day | Gray William GarrettChief Financial Officer | SSale | −74.1K | $3.67 | −$272.0K | −4.8%1.46M after | |
| Dec 20, 2024 (view filing) | Dec 18-19 | 2 days | Oliviero James F IIICEO, President and Director | SSale | −822.4K | $3.74 | −$3.07M | −20.5%3.19M after | 2 lots |
| Dec 20, 2024 (view filing) | Dec 18 | 2 days | Gray William GarrettChief Financial Officer | SSale | −268.4K | $4.01 | −$1.08M | −20.6%1.03M after | |
| Jun 28, 2024 (view filing) | Jun 26 | 2 days | Oliviero James F IIICEO, President and Director | SSale | −24.6K | $2.05 | −$50.5K | −1.2%1.98M after | |
| Jun 28, 2024 (view filing) | Jun 26 | 2 days | Gray William GarrettChief Financial Officer | SSale | −13.0K | $2.06 | −$26.9K | −1.9%672.2K after | |
| Mar 1, 2024 (view filing) | Feb 28 | 2 days | Oliviero James F IIICEO, President and Director | SSale | −5.89K | $2.06 | −$12.1K | −1.7%350.8K after | |
| Mar 1, 2024 (view filing) | Feb 28 | 2 days | Gray William GarrettChief Financial Officer | SSale | −2.04K | $2.07 | −$4.21K | −1.4%145.2K after | |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Gray William GarrettChief Financial Officer | SSale | −4.12K | $1.95 | −$8.02K | −2.7%147.3K after | |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Oliviero James F IIICEO, President and Director | SSale | −11.9K | $2.01 | −$23.9K | −3.1%369.7K after | |
| Mar 3, 2023 (view filing) | Feb 27-Mar 2 | 4 daysLate | Oliviero James F IIICEO, President and Director | SSale | −11.0K | $4.82 | −$53.2K | −7.1%144.1K after | 2 lots |
| Mar 3, 2023 (view filing) | Feb 27-Mar 2 | 4 daysLate | Gray William GarrettChief Financial Officer | SSale | −5.50K | $4.88 | −$26.9K | −9.7%51.4K after | 2 lots |
| Feb 3, 2023 (view filing) | Feb 1 | 2 days | Gray William GarrettChief Financial Officer | SSale | −3.15K | $4.79 | −$15.1K | −6.0%49.4K after | |
| Feb 3, 2023 (view filing) | Feb 1 | 2 days | Oliviero James F IIICEO, President and Director | SSale | −10.3K | $4.77 | −$48.9K | −5.3%182.1K after | |
| Jan 12, 2023 (view filing) | Jan 10 | 2 days | Gray William GarrettChief Financial Officer | SSale | −1.86K | $6.75 | −$12.5K | −3.4%52.5K after | |
| Jan 12, 2023 (view filing) | Jan 10 | 2 days | Oliviero James F IIICEO, President and Director | SSale | −3.82K | $6.75 | −$25.8K | −1.9%192.4K after | |
| Jul 1, 2022 (view filing) | Jun 17-23 | 14 daysLate | Oliviero James F IIICEO, President and Director | SSale | −276.0K | $1.09 | −$301.1K | −9.7%2.56M after | 4 lots |
| Apr 22, 2022 (view filing) | Apr 4-13 | 18 daysLate | Oliviero James F IIICEO, President and Director | SSale | −121.6K | $1.74 | −$211.5K | −4.1%2.84M after | 3 lots |
| Mar 11, 2022 (view filing) | Mar 10 | 1 day | Gray William GarrettChief Financial Officer | SSale | −38.2K | $1.89 | −$72.2K | −6.6%543.9K after | |
| Feb 2, 2022 (view filing) | Feb 1 | 1 day | Gray William GarrettChief Financial Officer | SSale | −37.1K | $2.51 | −$93.0K | −6.0%582.1K after |